Advances on the roles of tenascin-C in cancer |
|
Author: | Yilmaz, Alev1,2,3; Loustau, Thomas1,2,3; Salomé, Nathalie1,2,3; |
Organizations: |
1The Tumor Microenvironment Laboratory, INSERM U1109, Hôpital Civil, Institut d'Hématologie et d'Immunologie, 1 Place de l'Hôpital, 67091 Strasbourg, France 2Université Strasbourg, 67000 Strasbourg, France 3Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France
4Department of Cell Biology and Human Anatomy, University of California at Davis, 95616 Davis, CA, USA
5Faculty of Biochemistry and Molecular Medicine, University of Oulu, FI-90014 Oulu, Finland 6Faculty of Medicine, University of Oulu, FI-90014 Oulu, Finland 7Institute for Dental Research and Oral Musculoskeletal Research, Center for Biochemistry, Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Joseph-Stelzmann-Str. 52, 50931 Cologne, Germany |
Format: | article |
Version: | published version |
Access: | open |
Online Access: | PDF Full Text (PDF, 3.1 MB) |
Persistent link: | http://urn.fi/urn:nbn:fi-fe2022101461991 |
Language: | English |
Published: |
Company of Biologists,
2022
|
Publish Date: | 2022-10-14 |
Description: |
AbstractThe roles of the extracellular matrix molecule tenascin-C (TNC) in health and disease have been extensively reviewed since its discovery over 40 years ago. Here, we will describe recent insights into the roles of TNC in tumorigenesis, angiogenesis, immunity and metastasis. In addition to high levels of expression in tumors, and during chronic inflammation, and bacterial and viral infection, TNC is also expressed in lymphoid organs. This supports potential roles for TNC in immunity control. Advances using murine models with engineered TNC levels were instrumental in the discovery of important functions of TNC as a danger-associated molecular pattern (DAMP) molecule in tissue repair and revealed multiple TNC actions in tumor progression. TNC acts through distinct mechanisms on many different cell types with immune cells coming into focus as important targets of TNC in cancer. We will describe how this knowledge could be exploited for cancer disease management, in particular for immune (checkpoint) therapies. see all
|
Series: |
Journal of cell science |
ISSN: | 0021-9533 |
ISSN-E: | 1477-9137 |
ISSN-L: | 0021-9533 |
Volume: | 135 |
Issue: | 18 |
DOI: | 10.1242/jcs.260244 |
OADOI: | https://oadoi.org/10.1242/jcs.260244 |
Type of Publication: |
A2 Review article in a scientific journal |
Field of Science: |
3122 Cancers |
Subjects: | |
Funding: |
G.O. is supported by Institut National de la Santéet de la Recherche Médicale (INSERM), University Strasbourg, INCa project TENMAX, Agence Nationale de la Recherche (ANR) project MatrixNash, Aviesan ITMO Cancer project Radio3R, Ligue contre le cancer CCIRGE and EUCOR. VI is supported by the Academy of Finland (project number 326291), the University of Oulu DigiHealth-project, and the Finnish Cancer Institute, K. Albin Johansson Cancer Research Fellowship fund. M.K. is supported by Deutsche Forschungsgemeinschaft project ID FOR2722-384170921. C.L. is supported by a fellowship from the Chinese Scholarship Council. Open Access funding provided by INSERM. Deposited in PMC for immediate release. |
Copyright information: |
© 2022. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
https://creativecommons.org/licenses/by/4.0/ |